Abstract: . . .  trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg . 1999;230:466470. Grines et al Angiogenic Gene Therapy Trial 1297  . . .
. . .  of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg . 1999;230:466470. Grines et al Angiogenic Gene Therapy Trial 1297  . . .
. . .  angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg . 1999;230:466470. Grines et al Angiogenic Gene Therapy Trial 1297  . . .
. . .  resulted in 98% first-pass uptake, providing relative targeting of gene transfer to the heart. To determine the safety and potential clinical efficacy of gene transfer for the treatment of angina , we conducted the Angiogenic GENe Therapy (AGENT) trial, the first multicenter, randomized, double-blind, placebo- controlled trial of a potential angiogenic gene therapy. Methods Product Ad5-FGF4 consists of a human, replication-deficient, serotype 5 . . .
. . .  angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg . 1999;230:466470. Grines et al Angiogenic Gene Therapy Trial 1297  . . .
. . .  at 1 year after PTCA and CABG. Circulation . 1995;92(suppl II):II-1II-7. 16. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris : outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol . 1997;29:15051511. 17. Gilgenkrantz H, Duboc D, Juillard . . .
--3000,6,250,2572,49467